Hememics Biotechnologies Inc is categorized under Commercial Biotechnical Research in San Jose, CA and active since 2007.
Hememics Biotechnologies Inc was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Steve Bruttig at the company’s single location by writing to 1456 Sajak Avenue, San Jose, California CA 95131 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Hememics Biotechnologies Inc |
| Contact Person: | Steve Bruttig |
| Address: | 1456 Sajak Avenue, San Jose, California 95131 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Hememics Biotechnologies Inc was started in 2007 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Steve Bruttig for inquiries that concern Hememics Biotechnologies Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Hememics Biotechnologies Inc can be found at the coordinates 37.383982,-121.884809 as well as the street address 1456 Sajak Avenue in San Jose, California 95131.
For its online presence, you may visit Hememics Biotechnologies Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.